ClinicalTrials.Veeva

Menu
C

CAN Community Health | Sarasota, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Lenacapavir
Islatravir
Bictegravir
GS-1720
Tenofovir Alafenamide
GS-4182
Doravirine
Emtricitabine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 5 total trials

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0...

Active, not recruiting
HIV-1 Infection
Drug: BIC/FTC/TAF
Drug: DOR/ISL

The goal of this clinical study is to test how well the study drug, lenacapavir (LEN), works in preventing the risk of HIV.

Active, not recruiting
Pre-Exposure Prophylaxis of HIV Infection
Drug: PTM F/TDF
Drug: Placebo SC LEN

The goal of this clinical study is to learn more about the experimental drugs GS-1720 and GS-4182; to compare the combination of GS-1720 and GS-4182...

Enrolling
HIV-1-Infection
Drug: Placebo to Match BVY
Drug: Placebo to Match GS1720/GS-4182 FDC

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regi...

Enrolling
HIV-1-infection
Drug: B/F/TAF
Drug: PTM ISL/LEN

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Enrolling
HIV-1-infection
Drug: B/F/TAF
Drug: Placebo to match B/F/TAF

Trial sponsors

Gilead Sciences logo
Merck Sharp & Dohme (MSD) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems